ProMIS Neurosciences Inc. (PMN) stock
PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.29−0.19 (-5.46%)
Close on Nov 13, 2026Market cap $29.50MP/E –Yield –
ProMIS Neurosciences r&d expenses
Research and development expenses are spending on new products and technology.
ProMIS Neurosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $32.57M, up 14.9% year over year. For fiscal 2025 it was $33.38M, up 213.8% from the year before. The highest annual figure on record is $33.38M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.38M | +213.8% |
| FY2024 | Dec 31, 2024 | $10.64M | +34.9% |
| FY2023 | Dec 31, 2023 | $7.88M | -51.0% |
| FY2022 | Dec 31, 2022 | $16.09M | +247.7% |
| FY2021 | Dec 31, 2021 | $4.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.71M | -31.5% |
| Q2 FY2026 | Jun 30, 2026 | $9.52M | +8.8% |
| Q1 FY2026 | Mar 31, 2026 | $6.97M | +27.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.37M | +116.6% |
| Q3 FY2025 | Sep 30, 2025 | $9.80M | +282.1% |
| Q2 FY2025 | Jun 30, 2025 | $8.75M | +438.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.46M | +157.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.32M | +94.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.56M | +124.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.63M | +61.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.12M | -39.5% |
| Q4 FY2023 | Dec 31, 2023 | $2.23M | -65.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.14M | -75.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.01M | -68.9% |
| Q1 FY2023 | Mar 31, 2023 | $3.51M | +84.5% |
| Q4 FY2022 | Dec 31, 2022 | $6.38M | +124.2% |
| Q3 FY2022 | Sep 30, 2022 | $4.57M | +467.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.23M | +328.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.90M | – |
| Q4 FY2021 | Dec 31, 2021 | $2.85M | – |
| Q3 FY2021 | Sep 30, 2021 | $805.39K | – |
| Q2 FY2021 | Jun 30, 2021 | $754.30K | – |
See a number that looks wrong?